[Systemic candidiasis and infliximab therapy].
The use of infliximab in patients with luminal or fistulizing Crohn's disease refractory to medical treatment (steroids and immunomodulatory drugs) is increasingly widespread. Although the incidence of serious infections in patients undergoing infliximab treatment is not higher than that of controls, systemic fungal infections in patients treated with this antibody have been anecdotally described. We report a case of systemic candidiasis in a patient with refractory Crohn's disease who was treated with infliximab associated with corticosteroids and azathioprine and discuss the role that infliximab could have played in the development of this complication.
Belda
A
A
Unidad de Aparato Digestivo, Servicio de Medicina Interna, Hospital de Sagunto, Sagunto, Valencia, España.
Hinojosa
J
J
Serra
B
B
García
L
L
Merino
C
C
Belda
A
A
Molés
J R
JR
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D000935:Antifungal Agents / Q000627:therapeutic use; D002177:Candidiasis / Q000139:chemically induced*; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D016469:Fungemia / Q000139:chemically induced*; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D000069285:Infliximab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000935:Antifungal Agents; D005765:Gastrointestinal Agents; D000069285:Infliximab